Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice.

IF 2.7 4区医学 Q2 GENETICS & HEREDITY

Genes and Environment Pub Date : 2024-02-20 DOI:10.1186/s41021-024-00299-4

Takako Iso, Kenichiro Suzuki, Yasumasa Murata, Nozomu Hirose, Takaaki Umano, Katsuyoshi Horibata, Kei-Ichi Sugiyama, Akihiko Hirose, Kenichi Masumura, Mariko Matsumoto

{"title":"Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice.","authors":"Takako Iso, Kenichiro Suzuki, Yasumasa Murata, Nozomu Hirose, Takaaki Umano, Katsuyoshi Horibata, Kei-Ichi Sugiyama, Akihiko Hirose, Kenichi Masumura, Mariko Matsumoto","doi":"10.1186/s41021-024-00299-4","DOIUrl":null,"url":null,"abstract":"Background: Carbendazim (methyl 2-benzimidazolecarbamate, CASRN: 10605-21-7) exhibits spindle poisoning effects and is widely used as a fungicide. With respect to genotoxicity, carbendazim is deemed to be non-mutagenic in vitro, but it causes indicative DNA damage in vivo and chromosome aberrations in vitro and in vivo. In this study, we examined the mutagenicity of carbendazim in vivo.Results: MutaMice were treated with carbendazim orally at doses of 0 (corn oil), 250, 500, and 1,000 mg/kg/day once a day for 28 days. A lacZ assay was used to determine the mutant frequency (MF) in the liver and glandular stomach of mice. MutaMice were administered up to the maximum dose recommended by the Organization for Economic Co-operation and Development Test Guidelines for Chemicals No. 488 (OECD TG488). The lacZ MFs in the liver and glandular stomach of carbendazim-treated animals were not significantly different from those in the negative control animals. In contrast, positive control animals exhibited a significant increase in MFs in both the liver and glandular stomach.Conclusions: Carbendazim is non-mutagenic in the liver and glandular stomach of MutaMice following oral treatment.","PeriodicalId":12709,"journal":{"name":"Genes and Environment","volume":"46 1","pages":"7"},"PeriodicalIF":2.7000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877847/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes and Environment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s41021-024-00299-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Carbendazim (methyl 2-benzimidazolecarbamate, CASRN: 10605-21-7) exhibits spindle poisoning effects and is widely used as a fungicide. With respect to genotoxicity, carbendazim is deemed to be non-mutagenic in vitro, but it causes indicative DNA damage in vivo and chromosome aberrations in vitro and in vivo. In this study, we examined the mutagenicity of carbendazim in vivo.

Results: MutaMice were treated with carbendazim orally at doses of 0 (corn oil), 250, 500, and 1,000 mg/kg/day once a day for 28 days. A lacZ assay was used to determine the mutant frequency (MF) in the liver and glandular stomach of mice. MutaMice were administered up to the maximum dose recommended by the Organization for Economic Co-operation and Development Test Guidelines for Chemicals No. 488 (OECD TG488). The lacZ MFs in the liver and glandular stomach of carbendazim-treated animals were not significantly different from those in the negative control animals. In contrast, positive control animals exhibited a significant increase in MFs in both the liver and glandular stomach.

Conclusions: Carbendazim is non-mutagenic in the liver and glandular stomach of MutaMice following oral treatment.

查看原文本刊更多论文

多菌灵对 MutaMice 的肝脏和腺胃没有体内诱变性。

背景：多菌灵（2-苯并咪唑氨基甲酸甲酯，化学文摘社编号：10605-21-7）具有纺锤体中毒作用，被广泛用作杀菌剂。在遗传毒性方面，多菌灵在体外被认为不具有致突变性，但在体内会造成指示性 DNA 损伤，并在体外和体内造成染色体畸变。本研究考察了多菌灵在体内的致突变性：对突变小鼠口服多菌灵，剂量分别为 0（玉米油）、250、500 和 1,000 毫克/千克/天，每天一次，连续 28 天。采用 lacZ 检测法确定小鼠肝脏和腺胃中的突变频率（MF）。MutaMice 的给药剂量达到了《经济合作与发展组织化学品试验准则第 488 号》（OECD TG488）建议的最大剂量。经多菌灵处理的动物肝脏和腺胃中的 lacZ MFs 与阴性对照组动物的没有明显差异。相比之下，阳性对照组动物肝脏和腺胃中的 lacZ MFs 均有显著增加：结论：口服多菌灵不会对Muta小鼠的肝脏和腺胃产生致突变作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genes and Environment Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Genes and Environment is an open access, peer-reviewed journal that aims to accelerate communications among global scientists working in the field of genes and environment. The journal publishes articles across a broad range of topics including environmental mutagenesis and carcinogenesis, environmental genomics and epigenetics, molecular epidemiology, genetic toxicology and regulatory sciences. Topics published in the journal include, but are not limited to, mutagenesis and anti-mutagenesis in bacteria; genotoxicity in mammalian somatic cells; genotoxicity in germ cells; replication and repair; DNA damage; metabolic activation and inactivation; water and air pollution; ROS, NO and photoactivation; pharmaceuticals and anticancer agents; radiation; endocrine disrupters; indirect mutagenesis; threshold; new techniques for environmental mutagenesis studies; DNA methylation (enzymatic); structure activity relationship; chemoprevention of cancer; regulatory science. Genetic toxicology including risk evaluation for human health, validation studies on testing methods and subjects of guidelines for regulation of chemicals are also within its scope.